Keywords
Ambulatory Care
Men’s Health
Prostatic Hyperplasia
Unified Health System
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To estimate the direct costs of outpatient oncological care in Juiz de Fora for prostate cancer in the Unified Health System, from 2009 to 2018. Methods: Descriptive, retrospective and horizontal study. A partial economic analysis was developed to verify the direct costs in the treatment of prostatic neoplasia in a pole city of the macro-region southeast of Minas Gerais. The medical records were selected using the ICD-10 and the data collected using the Datasus were analyzed using the TabWin software. Results: 94,001 procedures performed on 2,303 patients were selected, with a mean of 38.7±43.01 (Md±SD) procedures per patient. Age ranged between 60 and 97 years. Attendances were distributed among the hospitals: Ascomcer (32.4%); Dr. João Felício (19.7%); Oncology (47.8%). A total of 94,001 procedures were paid, with a total cost of BRL 35,858, 257.15 and an average cost per procedure of BRL 381.47±472.28 (Md±SD). Conclusion: The high costs presented in these ten years show the seriousness of the problem of prostate cancer, which requires more effective prevention strategies.
References
ABDELKAREM OAI, et al. Effect of race and ethnicity on risk of radiotherapy toxicity and implications for radiogenomics. Clin Oncol (R Coll Radiol)., 2022; 34(10): 653-69.
ALMEIDA TS, et al. The auditor's nurse's performance in the quality of health care: integrative bibliographic review. Rev Adm Saúde, 2021; 21(83): e303.
BRASIL. Ministério da Saúde. Departamento de Informática do Sistema Único de Saúde.2022 Disponível em: https://datasus.saude.gov.br. Acessado em: 21 de novembro de 2022.
BRASIL. Decreto nº 7.508, de 28 de junho de 2011. Diário Oficial da União.2011. Disponível em: https://www.planalto.gov.br/ccivil_03/_Ato2011-2014/2011/Decreto/D7508.html. Acessado em: 21 de novembro de 2022.
BRASIL. Lei Complementar nº 141, de 13 de janeiro de 2012. Diário Oficial da União. 2012 Disponível em: https://www.planalto.gov.br/ccivil_03/leis/lcp/lcp141.html. Acessado em: 21 de novembro de 2022.
BRASIL. Ministério da Saúde. Fórum Tabwin. 2008. Disponível em: http://siab.datasus.gov.br/DATASUS/index.php?area=060805&item=3. Acessado em: 21 de novembro de 2022.
BRASIL. Ministério da Saúde. Informações de saúde: tabnet. Disponível em: https://datasus.saude.gov.br/informacoes-de-saude-tabnet. Acessado em: 21 de novembro de 2022.
BRASIL. Secretaria de Saúde. Prefeitura de Juiz de Fora. A estratégia de implantação do Plano Diretor da Atenção Primária em Saúde. Juiz de Fora: Secretaria de Saúde. 2014. Disponível em: https://www.pjf.mg.gov.br/secretarias/ss/plano_diretor/docs/normas_apsjf_2016.pdf. Acessado em: 21 de novembro de 2022.
BRASIL. Ministério da Saúde. Portaria nº 1.944, de 27 de agosto de 2009. Diário Oficial da União. 2009. Disponível em: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2009/prt1944_27_08_2009.html. Acessado em: 21 de novembro de 2022.
CHAGAS DNP, et al. Autocuidado do homem pós-alta hospitalar: perspectivas para o cuidado de enfermagem numa abordagem domiciliar. Enf Br., 2020; 19(5): 361-71.
HAMDY FC, et al. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localized prostate cancer: the protecT three-arm RCT. Health Technol Assess, 2020; 24(37): 1-176.
HENDRIX N, et al. Clarifying the trade-offs of risk-stratified screening for prostate cancer: a cost-effectiveness study. American Journal of Epidemiology, 2021; 190(10): 2064-74.
INSTITUTO NACIONAL DO CÂNCER (BR). Síntese de resultados e comentários. 2020. Disponível em: https://www.inca.gov.br/estimativa/sintese-de-resultadosecomentarios. Acessado em: 21 de novembro de 2022.
JARATLERDSIRI W, et al. African-specific molecular taxonomy of prostate cancer. Nature, 2022; 609(7927): 552-59.
KONSKI A. Cost effectiveness of prostate cancer radiotherapy. Transl Androl Urol., 2018; 7(3): 371-7.
MAURICE MJ, et al. Current status of prostate cancer diagnosis and management in the United States. JAMA Oncol., 2016; 2(11): 1505-7.
MELO LD, et al. Concepções de idosos sobre as políticas (inter)nacionais do envelhecimento humano. Refacs. 2020; 8(4): 865-81.
MELO LD, et al. Social representations of self-care in the perception of men with diabetes. Ciênc Cuid Saúde, 2022; 21: 1-9.
MOHLER JL, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw., 2019; 17(5): 479-505.
MONTAÑO JJ, et al. Prostate câncer survival by risk and Other prognostic Factors in Mallorca, Spain. Int J Environ Res Publ Health, 2021; 18: e11156.
NGUYEN PL, et al. Cost implications of the rapid Adoption of newer Technologies for treating prostate cancer. J Clin Oncol., 2011; 29(12): 1517-24.
O’MAHONY JF. Comment on Keeney et al.’s “Delphi analysis of relevant comparators in a cost effectiveness model of prostate cancer screening”. Pharmaco Economics, 2021; 39: 965-67.
ORGANIZAÇÃO MUNDIAL DA SAÚDE. Classificação internacional de doenças e problemas relacionados a saúde. 2002. Disponível em: https://concla.ibge.gov.br/classificacoes/por-tema/saude/cid-10.html. Acessado em: 21 de novembro de 2022.
OSSORIO AJL, et al. Una actualización en el protocolo en cáncer de próstata metastático hormonosensible. Act Urol Esp., 2022; 2: 1-22.
PITANGA AF. Pesquisa qualitativa ou pesquisa quantitativa: refletindo sobre as decisões na seleção de determinada abordagem. Rev Pesq Qualit., 2020; 8(17): 184-201.
RODRIGUEZ-ACEVEDO AJ, et al. Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia. BMC Cancer, 2021; 21: 1-12.
SÁNCHEZ-SÁNCHEZ K, et al. Prevalencia de factores de riesgo y sintomatología prostática en indígenas de Tabasco. Rev Cuidarte. 2021; 12(2): 1-13.
SCHROECK FR, et al. Cost of new Technologies in prostate cancer treatment: systematic review of costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton bem therapy. Eur Urol., 2017; 72(5): 712-35.
SILVA EP, et al. Older people's social representations of their social isolation during the Covid-19 pandemic. Rev Enf Ref., 2022; 1: e21075.
WANG F, et al. Prognostic comparison between radical prostatectomy and radiotherapy in prostate cancer patients at different stages and ages. Aging, 2021; 13(12): 1-12.